CRISPR Therapeutics and Vertex Pharmaceuticals unveiled early data from the first company-backed study to test a CRISPR-based medicine in humans. The data, from two patients with severe blood ...
EHA: Vertex, CRISPR build case for gene-editing drug A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update ...
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in 10 patients treated for a pair of blood disorders—sickle-cell disease (SCD) and beta ...
Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform in developing its CRISPR/Cas9-based ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Vertex Pharma and CRISPR Therapeutics have become the first companies to file for FDA approval of a therapy based on gene-editing technology. The two partners have submitted a marketing application ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Vertex Pharmaceuticals is paying $420 million upfront to go after the muscular dystrophy market. The outlay will give Vertex ownership of Exonics and expand its deal with CRISPR Therapeutics, setting ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals will work together with Orna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results